All In Biotech

Drug Trial Radar · NCT01509911

A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

Last checked: Nov 19, 2026Latest source record: Feb 5, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

99

Actual

Start

Jan 2012

Primary completion

Oct 2016

Study completion Jan 2017

Sponsor

Lead sponsor
Tiltan Pharma Ltd.Industry
Sponsor type
Industry
Collaborators
Technostat; Novatrials
First posted
Jan 13, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Tl-118 comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety. The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase II clinical trial aims to evaluate the efficacy, safety and tolerability of TL-118 in Gemcitabine treated Pancreatic Cancer patients

Conditions

  • Metastatic Pancreatic Cancer

Interventions

  • TL-118Drug

    TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.

  • GemcitabineDrug

    Monthly cycles of 3 weekly treatments a month and one week off of treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Control Rate as defined by Percentage of patients experiencing a Complete Response or a Partial Response or a Stable Disease according to RECIST measured at 16 weeks after treatment initiationTime frame: 16 weeks after treatment initiation

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Emory Clinic

    Atlanta, Georgia

  • White Plains Hospital

    White Plains, New York

  • HaEmek Medical Center

    Afula, Israel

  • Soroka Medical Center

    Beersheba, Israel

  • Hillel Yaffe Medical Center

    Hadera, Israel

  • Rambam Medical Center

    Haifa, Israel

  • Hadassah Medical Center

    Jerusalem, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • Assaf Harofe Medical Center

    Tsrifin, Zerifin, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.